Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 35 Lung Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Ovarian Neoplasms 5 Esophageal Neoplasms 5 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Retinoblastoma 2 Resectable Non-small Cell Lung Cancer 2 Neoplasms 2 Neoplasm Metastasis 2 Head and Neck Neoplasms 2 Urinary Bladder Neoplasms 1 Squamous-Cell Lung Cancer 1 Sjogren's Syndrome 1 Scleroderma, Systemic 1 Retinal Neoplasms 1 Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1 Resectable Lung Non-Small Cell Carcinoma 1 Recurrence 1 Psoriasis 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Ovarian Cancer Recurrent 1 Oropharyngeal Neoplasms 1 Nonsquamous Non-small Cell Lung Cancer 1 Non-Squamous Non-Small Cell Lung Cancer 1 NSCLC 1 Multiple Sclerosis 1

Interventions

pembrolizumab 2 toripalimab 1 sintilimab 1 pemigatinib 1 osimertinib 1 durvalumab 1 Vinorelbine 1 Platinum Compounds 1 Nivolumab 1 Ipilimumab 1 Drug Therapy 1 AZD 6244 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Non Small Cell Lung Cancer × Platinum Compounds × Clear all

NCT04144608 2024-08-09

TOGATHER

Hunan Province Tumor Hospital

Phase 2 Completed

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡